Implementation of a Cost and Variation Reduction Program for Hemostasis Products at a Large Academic Medical Center: A Multi-Stakeholder Perspective.

IF 1.3 Q4 ENGINEERING, BIOMEDICAL
Medical Devices-Evidence and Research Pub Date : 2025-01-24 eCollection Date: 2025-01-01 DOI:10.2147/MDER.S488279
Tejen Shah, Stacy Brethauer, Walter A Danker, Ishita Doshi, Matthew O'Hara, Abigail Silber, William K Vasileff
{"title":"Implementation of a Cost and Variation Reduction Program for Hemostasis Products at a Large Academic Medical Center: A Multi-Stakeholder Perspective.","authors":"Tejen Shah, Stacy Brethauer, Walter A Danker, Ishita Doshi, Matthew O'Hara, Abigail Silber, William K Vasileff","doi":"10.2147/MDER.S488279","DOIUrl":null,"url":null,"abstract":"<p><strong>Goal: </strong>Cost-saving initiatives targeting surgical supplies management have become increasingly common to address rising healthcare costs. However, few studies provide details on hospital stakeholder experiences or learnings from implementing such initiatives. Thus, we sought to evaluate hospital stakeholder satisfaction with conversion to a sole supplier for hemostasis products, in addition to economic and clinical impacts, to help develop best practices for implementation.</p><p><strong>Methods: </strong>This cross-sectional study assessed satisfaction with converting to a sole supplier for hemostasis products at a large US academic medical center using qualitative interviews and quantitative surveys with clinical and non-clinical stakeholders, on the decision-making process, conversion, and vendor-supported hemostasis optimization program (HOP) post-implementation (February 2022-May 2022). Perioperative hemorrhage events, adjunctive hemostat utilization, and total annual hospital expenditure on hemostatic products were also evaluated pre- and post-conversion (2020-2022) to identify impacts on clinical and economic outcomes.</p><p><strong>Findings: </strong>Ten hospital stakeholders completed qualitative interviews (n = 7 surgeons, n = 2 surgical technicians, n = 1 administrator) and 22 completed quantitative surveys (n = 6 surgeons, n = 5 surgical technicians, n = 11 nurses). Survey respondents noted overall satisfaction with conversion, including the level of input they provided in the decision-making process (75% were somewhat to extremely satisfied), availability of hemostatic agents during the conversion process (87%), and the vendor-supported HOP (100%). The outcomes analyses revealed a nearly 25% decrease in supply expenditure without changes to the number of postoperative hemorrhage events following implementation.</p><p><strong>Practical applications: </strong>Converting to a sole vendor for hemostasis products was achieved with high satisfaction among hospital stakeholders and cost savings to the institution without impacting the quality of patient care. This study provides a roadmap of best practices for other institutions interested in implementing similar initiatives and presents an example of a successful transition to a sole vendor for hemostasis products driven by effective supplier, institution, and hospital stakeholder coordination.</p>","PeriodicalId":47140,"journal":{"name":"Medical Devices-Evidence and Research","volume":"18 ","pages":"63-73"},"PeriodicalIF":1.3000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11774113/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Devices-Evidence and Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/MDER.S488279","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Goal: Cost-saving initiatives targeting surgical supplies management have become increasingly common to address rising healthcare costs. However, few studies provide details on hospital stakeholder experiences or learnings from implementing such initiatives. Thus, we sought to evaluate hospital stakeholder satisfaction with conversion to a sole supplier for hemostasis products, in addition to economic and clinical impacts, to help develop best practices for implementation.

Methods: This cross-sectional study assessed satisfaction with converting to a sole supplier for hemostasis products at a large US academic medical center using qualitative interviews and quantitative surveys with clinical and non-clinical stakeholders, on the decision-making process, conversion, and vendor-supported hemostasis optimization program (HOP) post-implementation (February 2022-May 2022). Perioperative hemorrhage events, adjunctive hemostat utilization, and total annual hospital expenditure on hemostatic products were also evaluated pre- and post-conversion (2020-2022) to identify impacts on clinical and economic outcomes.

Findings: Ten hospital stakeholders completed qualitative interviews (n = 7 surgeons, n = 2 surgical technicians, n = 1 administrator) and 22 completed quantitative surveys (n = 6 surgeons, n = 5 surgical technicians, n = 11 nurses). Survey respondents noted overall satisfaction with conversion, including the level of input they provided in the decision-making process (75% were somewhat to extremely satisfied), availability of hemostatic agents during the conversion process (87%), and the vendor-supported HOP (100%). The outcomes analyses revealed a nearly 25% decrease in supply expenditure without changes to the number of postoperative hemorrhage events following implementation.

Practical applications: Converting to a sole vendor for hemostasis products was achieved with high satisfaction among hospital stakeholders and cost savings to the institution without impacting the quality of patient care. This study provides a roadmap of best practices for other institutions interested in implementing similar initiatives and presents an example of a successful transition to a sole vendor for hemostasis products driven by effective supplier, institution, and hospital stakeholder coordination.

在一个大型学术医疗中心实施止血产品的成本和变化减少计划:多方利益相关者的观点。
目标:针对外科用品管理的成本节约举措已越来越普遍,以应对不断上升的医疗成本。然而,很少有研究提供医院利益相关者的经验或从实施这些举措中学习的细节。因此,除了经济和临床影响外,我们还试图评估医院利益相关者对转变为止血产品唯一供应商的满意度,以帮助制定实施的最佳做法。方法:本横断面研究通过对临床和非临床利益相关者的定性访谈和定量调查,评估了美国一家大型学术医疗中心转变为唯一止血产品供应商的满意度,包括决策过程、转换和供应商支持的止血优化计划(HOP)实施后(2022年2月至2022年5月)。还评估了转换前后(2020-2022年)围手术期出血事件、辅助止血药使用和止血产品的年度医院总支出,以确定对临床和经济结果的影响。结果:10名医院利益相关者完成了定性访谈(n = 7名外科医生,n = 2名外科技术员,n = 1名行政人员),22名完成了定量调查(n = 6名外科医生,n = 5名外科技术员,n = 11名护士)。调查对象指出了对转换的总体满意度,包括他们在决策过程中提供的投入水平(75%的人比较满意到非常满意),转换过程中止血剂的可用性(87%)以及供应商支持的HOP(100%)。结果分析显示,实施后,在没有改变术后出血事件数量的情况下,供应支出减少了近25%。实际应用:转变为止血产品的唯一供应商在医院利益相关者中获得了很高的满意度,并且在不影响患者护理质量的情况下为机构节省了成本。本研究为其他有兴趣实施类似举措的机构提供了最佳实践路线图,并展示了在供应商、机构和医院利益相关者有效协调的推动下成功过渡到止血产品唯一供应商的例子。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Medical Devices-Evidence and Research
Medical Devices-Evidence and Research ENGINEERING, BIOMEDICAL-
CiteScore
2.80
自引率
0.00%
发文量
41
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信